Hepatitis
Original Research
Outcomes and Barriers Associated with Telehealth-Based Hepatitis C Treatment During Early Phases of the COVID-19 Pandemic
The objective of this study was to evaluate HCV treatment at the beginning of the COVID-19 pandemic, when care was conducted virtually, by...
Commentary
The Breakthrough Drug Whose Full Promise Remains Unrealized
With its approval in 2013, sofosbuvir revolutionized the treatment of hepatitis C, but the goal of eliminating this disease is still decades away...
Latest News
NAFLD increases risk for severe infections
Physicians should assess their patients’ vaccination status and seek to control modifiable risk factors, such as diabetes.
Latest News
Dried blood spot test validated for HIV, hep B, and hep C
“This method is particularly useful in high-risk settings such as homeless shelters, drug rehabilitation centers, and prisons, where ... it can be...
News
Racial disparities not found in chronic hepatitis B treatment initiation
Treatment guidelines need to be simplified and that efforts to increase hepatitis B virus (HBV) awareness and train more clinicians are needed.
News
Likely cause of mysterious hepatitis outbreak in children identified
The study’s key messages for parents and health care providers “are awareness and reassurance,” Dr. Balistreri said in an interview.
Commentary
Celebrity death finally solved – with locks of hair
Case: A 56-year-old musician presents with diffuse abdominal pain, cramping, and jaundice. His medical history is notable for years of diffuse...
Commentary
The five biggest changes in the 2023 adult vaccine schedules
COVID vaccines are now front and center among 2023’s five most important changes.
News
Direct-acting antivirals tied to better outcomes in chronic Hep C
Researchers saw a significant reduction in all-cause mortality over a decade with direct-acting antivirals compared with no treatment.
News
FDA rejects bulevirtide for hepatitis D
The FDA cited concerns over the production and delivery of bulevirtide, an investigational, first-in-class hepatitis delta virus entry-inhibitor...